<DOC>
	<DOCNO>NCT00164411</DOCNO>
	<brief_summary>The purpose study learn whether give tetanus/diphtheria vaccination ( `` tetanus shot '' ) give pneumococcal vaccine make pneumococcal vaccine effective without cause many side effect .</brief_summary>
	<brief_title>Pneumococcal Conjugate Vaccine With Pneumococcal Polysaccharide Vaccine Tetanus/Diphtheria Vaccine</brief_title>
	<detailed_description>The vaccine license United States protect adult pneumococcal disease ( PPV23 ) protect invasive disease observational study generally poorly effective pneumonia all-cause mortality randomize clinical trial . Another vaccine contain seven polysaccharide antigen conjugate diphtheria toxoid ( PCV7 ) license child investigation adult . In pilot study , compare safety immunogenicity three immunization schedule adult : - Td vaccine , 2-week interval , PCV7 , 4-month interval , PPV23 - PCV7 , 4-month interval , PPV23 - PPV23 We aim : - compare safety profile pneumococcal vaccine give three schedule - compare serotype-specific ELISA antibody response pneumococcal antigen give three schedule - compare functional serotype-specific antibody responses pneumococcal antigen give three schedule - study influence diphtheria antibody level time pneumococcal conjugate vaccine administration magnitude immune response pneumococcal antigen</detailed_description>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Participation investigational clinical trial except purely observational study within 4 week prior study start Any vaccination within 2 week prior first study vaccine Evidence systemic local infection within one week prior first study vaccine HIV infection Renal failure Receipt pneumococcal Td vaccine within 5 year Current receipt therapy neoplastic disease Current receipt immunosuppressive therapy Terminal illness withlife expectancy le 3 month</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Diptheria-Tetanus vaccine</keyword>
	<keyword>Pneumococcal vaccine</keyword>
	<keyword>Adverse event follow vaccination</keyword>
	<keyword>Immunization</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>